US Stock MarketDetailed Quotes

PTGX Protagonist Therapeutics

Watchlist
  • 37.750
  • -0.920-2.38%
Close Feb 18 16:00 ET
  • 37.750
  • +0.000+0.00%
Post 18:08 ET
2.25BMarket Cap13.78P/E (TTM)

About Protagonist Therapeutics Company

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Company Profile

SymbolPTGX
Company NameProtagonist Therapeutics
Listing DateAug 11, 2016
Issue Price12.00
Founded2006
CEODr. Dinesh V. Patel, PhD
MarketNASDAQ
Employees112
Fiscal Year Ends12-31
Address7707 Gateway Boulevard,Suite 140
CityNewark
ProvinceCalifornia
CountryUnited States of America
Zip Code94560-1160
Phone1-510-474-0170
Websitehttp://www.protagonist-inc.com

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Dinesh V. Patel, PhD
  • Director, President and Chief Executive Officer
  • 7.07M
  • Asif Ali
  • Executive Vice President, Principal Accounting Officer and Chief Financial Officer
  • 1.40M
  • Dr. Arturo Molina, M.D.
  • Chief Medical Officer
  • --
  • Dr. Suneel Gupta, PhD
  • Executive Vice President, Clinical Development
  • 2.22M
  • Dr. Harold E. Selick, PhD
  • Chairman of the Board
  • 395.27K
  • Sarah A. O’Dowd
  • Independent Director
  • 341.52K
  • Bryan Giraudo
  • Independent Director
  • 356.52K
  • Dr. Lewis T. Willia M.D.,PhD
  • Independent Director
  • 351.52K
  • William D. Waddill
  • Independent Director
  • 364.02K

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
HENDERA
831152
+30.00%
Hengerda New Materials
300946
+20.01%
Fujian Nebula Electronics.,Ltd
300648
+20.00%
4
Cubic Digital Technology
300344
+19.98%
5
HNAC Technology
300490
+19.95%
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
FOMC leaves rates unchanged, how will you adjust your portfolio?
FOMC left the target Federal Funds rate unchanged at at target of 4.25%-4.5%, how will you adjust your portfolio? Show More
FOMC Press Conference, January 29, 2025